New intranasal influenza vaccine triggers robust immunity with significantly le...( Washington DC (October 26 2008) A si...),Health
Washington, DC (October 26, 2008) A single administration of a novel, nasally delivered influenza vaccine elicited immune responses in ferrets that were more than 20 times higher than those generated by two injections of the currently approved vaccines, according to a study by NanoBio Corporation. The new vaccine used only half the standard antigen dose to produce this effect.
Results of the study are being presented today at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.
The company's nasal vaccines exert adjuvant activity without the need for pro-inflammatory materials, toxins or cytokines.
"Our nanoemulsion-based intranasal vaccine adjuvant system represents a paradigm shift in vaccinology. It can be used to safely deliver multiple antigen types directly into the lining of the nasal mucosa, which is rich in dendritic cells that present the antigen(s) to the immune system," said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. "The nanoemulsion adjuvant uniquely interacts with these cells to trigger unparalleled mucosal and systemic immunity."
In the study, ferrets received 7.5, 15 and 45 micrograms of nanoemulsion-adjuvanted influenza vaccine (n=12 ferrets/dose). All three doses produced antibody responses substantially higher than those triggered by the standard intramuscular vaccine. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live influenza virus, and all were protected.
"A large, unmet medical need still exists for protecting people from influenza infection," Baker said. "The robust immunity and antigen-sparing capability demonstrated in this study are especially important for addressing this unmet need, as are the demands for a vaccine that would protect people in the face of a flu pandemic."
Nan
'/>"/>
| Contact: Becky Levine blevine@medthink.com 919-786-4918 MedThink Communications Source:Eurekalert |
Related medicine news :
1. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
2. Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
3. Bioniche Responds to Australian Equine Influenza Outbreak
4. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
5. NIH scientists describe ways to better assess benefits of influenza vaccine in the elderly
6. Launch of New Educational Campaign, Spread the Word - NOT the Flu!, Aims to Highlight Importance of Influenza Vaccination
7. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
8. Influenza: Insights into cell specificity of human vs. avian viruses
9. Childhood Influenza Immunization Coalition Issues New Report to Help Improve Low Childhood Influenza Immunization Rates
10. Health Department Reports States First Lab-Confirmed Influenza Case of the Season
11. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |